image description

Lars Rueve

European Counsel

Lars Rueve

European Counsel
Frankfurt +49-69-4272-5200+49-69-4272-5200 +49-69-4272-5210+49-69-4272-5210
[email protected]
Lars Rueve is a European Counsel in S&C’s Frankfurt office and a member of our German law practice group. He has extensive experience in capital markets and M&A transactions as well as in general securities and corporate law matters, such as capital markets compliance and post-admission obligations, shareholders’ meetings, corporate governance and executive compensation. 

Mr. Rueve studied law at the Westfaelische Wilhelms-Universitaet Muenster, Germany, continued his legal studies at the University of Virginia School of Law, Virginia, USA, graduating as LL.M., and earned his Dr. jur. degree from the Ludwig-Maximilians-Universitaet Muenchen, Germany. 


 


SELECTED REPRESENTATIONS

Recent Capital Markets transactions
From 2018 to 2020, Dr. Rueve has advised: 
  • Activum on its €390 million private placement of Instone Real Estate shares 
  • Bayer on its €6 billion rights issue and its €3 billion issue of new shares to Temasek in connection with the refinancing of the Monsanto acquisition
  • Delivery Hero on its €571 million issue of new shares and its €1.75 billion and €1.5 billion convertible bond offerings
  • Dermapharm on its €377 million IPO and listing on the Frankfurt Stock Exchange
  • Underwriters on DWS Group’s €1.4 billion IPO and listing on the Frankfurt Stock Exchange
  • HelloFresh on its €175 million convertible bond offering
  • home24 on its €600 million IPO and listing on the Frankfurt Stock Exchange
  • Hypo Real Estate on its €287 million private placement of Deutsche Pfandbriefbank shares
  • Instone on its €428 million IPO-dual track transaction
  • Rocket Internet on its €324 million public share purchase offer alongside United Internet’s public share purchase offer
  • Underwriters on Siemens Healthineers’ €4.2 billion IPO and listing on the Frankfurt Stock Exchange 
  • TLG IMMOBILIEN on its €222 million issue of new shares
  • Westwing on its €520 million IPO and listing on the Frankfurt Stock Exchange 

Further key Capital Markets transactions
Over the past 10 years, Dr. Rueve has worked on many high-profile transactions, including:
  • IPOs/listings of: Covestro; Delivery Hero; Deutsche Annington/Vonovia; Deutsche Pfandbriefbank; Evonik Industries; HelloFresh; innogy; OFFICEFIRST Immobilien; Rocket Internet; Sixt Leasing; Tele Columbus; TLG IMMOBILIEN; windeln.de and Zalando.
  • Rights issues of: Commerzbank; Draegerwerk; IVG Immobilien; Porsche Automobil Holding; Schaeffler and Tele Columbus.
  • Primary placements of: Deutsche Annington/Vonovia; Deutsche Wohnen; PAION; ProSiebenSat.1 and TLG IMMOBILIEN.
  • Secondary placements for: Goldman Sachs and KKR of their KION shares; Oaktree of its alstria REIT shares; pre-IPO shareholders of their Zalando shares; Siemens of its Osram shares; several bookrunners in placements of secondary shares of Delivery Hero and Scout24.
  • Cornerstone investments in: Rocket Internet and Zalando in connection with their IPOs.
  • Share buy-back programs and public share purchase offers of several issuers.

Recent M&A transactions
From 2018 to 2020, Dr. Rueve has represented:
  • Owners of BEOS on their sale of the company to Swiss Life
  • Delivery Hero in its $4 billion agreement to acquire Woowa Brothers
  • Merck on its $6.5 billion acquisition of Versum Materials 
  • United Rentals in its $715 million acquisition of BakerCorp International

Further key M&A transactions
In addition, over the past 10 years Dr. Rueve has advised: 
  • CPPIB on its abandoned bid for Hochtief Airports
  • Drillisch on its €8 billion business combination with United Internet 
  • Hospira on its sale of Wasserburger Arzneimittelwerke to Recipharm
  • HSE Entsorgung on the sale of its water business to Skion 
  • Lone Star in connection with its tender offer for ISARIA Wohnbau
  • Rhône Capital on its sale of CSM Bakery’s fats business to AAK Belgium 
  • Rio Tinto on the sale of its German Alcan subsidiaries to Amcor
  • Shareholders on their sale of Novaled to Samsung Industries